Stem cell harvesting after bortezomib-based re-induction for myeloma relapsing after autologous transplant: results from the BSBMT/UKMF Myeloma X (Intensive) trial.
AffiliationSection of Experimental Haematology, Leeds Institute of Cancer & Pathology, University of Leeds, UK
MetadataShow full item record
AbstractThe phase III BSBMT/UKMF Myeloma X trial (MMX) demonstrated prospectively, for the first time, superiority of salvage autologous stem cell transplantation (ASCT2) over chemotherapy maintenance for multiple myeloma (MM) in first relapse after prior ASCT (ASCT1). However, many patients have insufficient stored stem cells (PBSC) for ASCT2 and robust evidence for remobilisation after ASCT1 is lacking. We therefore report on the feasibility, safety and efficacy of remobilisation after bortezomib-doxorubicin-dexamethasone reinduction in MMX, and outcomes of ASCT2 with these cells. 110 patients underwent ≥1 remobilisation with 32 and 4 respectively undergoing second and third attempts. Toxicities of remobilisation were similar to those seen in first line mobilisation. After all attempts, 52% of those with insufficient previously stored PBSC had harvested sufficient to proceed to ASCT2. Median PBSC doses infused, neutrophil engraftment and time to discharge after ASCT2 were similar irrespective of stem cell source, as were the toxicities of ASCT2. No significant differences between PBSC sources were noted in depth of response to ASCT or time to progression. Harvesting after bortezomib-doxorubicin-dexamethasone re-induction for MM at first relapse is safe and feasible, and yields a reliable cell product for second ASCT. The study is registered with ClinicalTrials.gov (NCT00747877) and EudraCT (2006-005890-24).
CitationStem cell harvesting after bortezomib-based re-induction for myeloma relapsing after autologous transplant: results from the BSBMT/UKMF Myeloma X (Intensive) trial. 2016: Biol Blood Marrow Transplant
JournalBiology of Blood and Marrow Transplantation
- High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
- Authors: Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group.
- Issue date: 2014 Jul
- The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
- Authors: Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group.
- Issue date: 2016 Jul
- The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
- Authors: Striha A, Ashcroft AJ, Hockaday A, Cairns DA, Boardman K, Jacques G, Williams C, Snowden JA, Garg M, Cavenagh J, Yong K, Drayson MT, Owen R, Cook M, Cook G
- Issue date: 2018 Mar 7
- Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
- Authors: Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y
- Issue date: 2009 Jul
- Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
- Authors: Zheng D, Li J, Huang BH, Liu JR, Zou WY, Su C
- Issue date: 2012 Dec